Attenuation	attenuation	O	O
of	of	O	O
methamphetamine-induced	methamphetamine-induced	O	O
nigrostriatal	nigrostriatal	O	O
dopaminergic	dopaminergic	S_chemicals	O
neurotoxicity	neurotoxicity	O	S_disease
in	in	O	O
mice	mice	O	O
by	by	O	O
lipopolysaccharide	lipopolysaccharide	S_chemicals	O
pretreatment	pretreatment	O	O
.	.	O	O

Immunological	immunological	O	O
activation	activation	O	O
has	has	O	O
been	been	O	O
proposed	proposed	O	O
to	to	O	O
play	play	O	O
a	a	O	O
role	role	O	O
in	in	O	O
methamphetamine-induced	methamphetamine-induced	O	O
dopaminergic	dopaminergic	S_chemicals	O
terminal	terminal	O	O
damage	damage	O	O
.	.	O	O

In	in	O	O
this	this	O	O
study	study	O	O
,	,	O	O
we	we	O	O
examined	examined	O	O
the	the	O	O
roles	roles	O	O
of	of	O	O
lipopolysaccharide	lipopolysaccharide	S_chemicals	O
,	,	O	O
a	a	O	O
pro-inflammatory	pro-inflammatory	O	O
and	and	O	O
inflammatory	inflammatory	O	O
factor	factor	O	O
,	,	O	O
treatment	treatment	O	O
in	in	O	O
modulating	modulating	O	O
the	the	O	O
methamphetamine-induced	methamphetamine-induced	O	O
nigrostriatal	nigrostriatal	O	O
dopamine	dopamine	S_chemicals	O
neurotoxicity	neurotoxicity	O	S_disease
.	.	O	O

Lipopolysaccharide	lipopolysaccharide	S_chemicals	O
pretreatment	pretreatment	O	O
did	did	O	O
not	not	O	O
affect	affect	O	O
the	the	O	O
basal	basal	O	O
body	body	O	B_disease
temperature	temperature	O	I_disease
or	or	O	O
methamphetamine-elicited	methamphetamine-elicited	O	O
hyperthermia	hyperthermia	O	S_disease
three	three	O	O
days	days	O	O
later	later	O	O
.	.	O	O

Such	such	O	O
systemic	systemic	O	O
lipopolysaccharide	lipopolysaccharide	S_chemicals	O
treatment	treatment	O	O
mitigated	mitigated	O	O
methamphetamine-induced	methamphetamine-induced	O	O
striatal	striatal	O	O
dopamine	dopamine	S_chemicals	O
and	and	O	O
3,4-dihydroxyphenylacetic	3,4-dihydroxyphenylacetic	O	O
acid	acid	S_chemicals	O
depletions	depletions	O	O
in	in	O	O
a	a	O	O
dose-dependent	dose-dependent	O	O
manner	manner	O	O
.	.	O	O

As	as	O	O
the	the	O	O
most	most	O	O
potent	potent	O	O
dose	dose	O	O
(	(	B_chemicals	O
1	1	I_chemicals	O
mg/kg	mg/kg	O	O
)	)	O	O
of	of	O	O
lipopolysaccharide	lipopolysaccharide	S_chemicals	O
was	was	O	O
administered	administered	O	O
two	two	O	O
weeks	weeks	O	O
,	,	O	O
one	one	O	O
day	day	O	O
before	before	O	O
or	or	O	O
after	after	O	O
the	the	O	O
methamphetamine	methamphetamine	S_chemicals	O
dosing	dosing	O	O
regimen	regimen	O	O
,	,	O	O
methamphetamine-induced	methamphetamine-induced	O	O
striatal	striatal	O	O
dopamine	dopamine	S_chemicals	O
and	and	O	O
3,4-dihydroxyphenylacetic	3,4-dihydroxyphenylacetic	O	O
acid	acid	S_chemicals	O
depletions	depletions	O	O
remained	remained	O	O
unaltered	unaltered	O	O
.	.	O	O

Moreover	moreover	O	O
,	,	O	O
systemic	systemic	O	O
lipopolysaccharide	lipopolysaccharide	S_chemicals	O
pretreatment	pretreatment	O	O
(	(	B_chemicals	O
1	1	I_chemicals	O
mg/kg	mg/kg	O	O
)	)	O	O
attenuated	attenuated	O	O
local	local	O	O
methamphetamine	methamphetamine	S_chemicals	O
infusion-produced	infusion-produced	O	O
dopamine	dopamine	S_chemicals	O
and	and	O	O
3,4-dihydroxyphenylacetic	3,4-dihydroxyphenylacetic	O	O
acid	acid	S_chemicals	O
depletions	depletions	O	O
in	in	O	O
the	the	O	O
striatum	striatum	O	O
,	,	O	O
indicating	indicating	O	O
that	that	O	O
the	the	O	O
protective	protective	O	O
effect	effect	O	O
of	of	O	O
lipopolysaccharide	lipopolysaccharide	S_chemicals	O
is	is	O	O
less	less	O	O
likely	likely	O	O
due	due	O	O
to	to	O	O
interrupted	interrupted	O	O
peripheral	peripheral	O	O
distribution	distribution	O	O
or	or	O	O
metabolism	metabolism	O	O
of	of	O	O
methamphetamine	methamphetamine	S_chemicals	O
.	.	O	O

We	we	O	O
concluded	concluded	O	O
a	a	O	O
critical	critical	O	O
time	time	O	O
window	window	O	O
for	for	O	O
systemic	systemic	O	O
lipopolysaccharide	lipopolysaccharide	S_chemicals	O
pretreatment	pretreatment	O	O
in	in	O	O
exerting	exerting	O	O
effective	effective	O	O
protection	protection	O	O
against	against	O	O
methamphetamine-induced	methamphetamine-induced	O	O
nigrostriatal	nigrostriatal	O	O
dopamine	dopamine	S_chemicals	O
neurotoxicity	neurotoxicity	O	S_disease
.	.	O	O

